Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2014 08:00 ET | Source: Prosensa Holding N.V.

Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy

Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating...